BoobyBiome, a trailblazing biotech company focused on protecting the breast milk microbiome, has successfully closed a £2.5M funding round to accelerate its groundbreaking research and product development.The investment will enable BoobyBiome to scale its proprietary technology that safeguards and harnesses beneficial microbes in breast milk, critical for supporting infant immune development and lifelong health outcomes. BoobyBiome’s Co-Founder & COO, Dr. Sioned Fôn Jones, previously spoke on stage at Women’s Health Week 2024 (previously SiS London), where the company connected with an investor who has since joined their cap table. This milestone is a powerful example of how WHW fosters meaningful connections that directly contribute to commercial success and global health impact.

Speaking about the announcement, Sioned said:

“We did it. A groundbreaking discovery, a product setting a new gold standard globally, and a £2.5M seed round bringing it to life today. I’m so proud of our team for dreaming boldly, for never giving up, and for building something that truly matters.”

Women’s Health Week: A Platform for Growth

At Women’s Health Week, we celebrate innovators like BoobyBiome who are transforming women’s health from underserved segment to global priority. Our flagship events in London and the USA bring together growth-stage companies, strategic investors, and multinational partners to accelerate commercial success and health impact at scale.

The success of BoobyBiome underscores the momentum in women’s health innovation, with significant investment flowing into maternal and infant health solutions. As the world’s leading platform dedicated to advancing women’s health, Women’s Health Week showcases growth-stage innovators across biotech, digital health, consumer health, and medical devices. By connecting startups, corporates, and investors, WHW accelerates the partnerships and deal flow that drive transformative change in women’s healthcare globally.